Skip Navigation


Journal of Biochemistry Advance Access originally published online on May 21, 2007
Journal of Biochemistry 2007 142(1):17-24; doi:10.1093/jb/mvm111
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
142/1/17    most recent
mvm111v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zhiyi, H.
Right arrow Articles by Qing, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhiyi, H.
Right arrow Articles by Qing, Z.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 The Japanese Biochemical Society.

Secretion Expression and Activity Assay of a Novel Fusion Protein of Thrombopoietin and Interleukin-6 in Pichia pastoris

Hu Zhiyi1, Lai Wenshan2, Zhang Wenze3, Deng Ning4, Zhang Chi2, Ye Kenan3, Wang Ping3, Wang Qianqian3 and Zhang Qing3,*

1National Key Discipline Department Of Internal Medicine, The First School Of Medicine, Guangzhou University of Chinese Medicine 510405, China; 2School of Pharmaceutical Sciences, Zhongshan (SUN YAT-SUN) University; 3Biotechnology Research Center, Key Laboratory Of Gene Engineering of the Education Ministry, School of Life Science, Zhongshan (SUN YAT-SUN) University, Guangzhou, 510275, China; and 4College of Life Science and Technology, Jinan University, Guangzhou, 510632, China

*To whom correspondence should be addressed. Tel: 86-20-84113988, Fax: +86-20-84036551, E-mail: lsszq{at}mail.sysu.edu.cn

Received March 4, 2007; Accepted March 22, 2007


   Abstract

Thrombopoietin (TPO) is an important haematopoietic factor in megakaryocytic activities as well as in platelet production. Interleukin 6 (IL-6) can co-stimulate TPO-dependent formation of colony forming unit of megakaryocyte (CFU-Meg) growth which could be responsible for residual platelet formation in TPO-deficient or c-mpl-deficient animals. In this report, we demonstrated the development of a high-level expression system to produce a 78-kDa human fusion protein IL-6/TPO (named ZH646). This was achieved by constructing the expression vector pPICZ{alpha}-A-IL-6-linker-TPO, and obtained the recombinant yeast GS115, which then efficiently secreted into a medium with a yield of 30 mg/l from the supernatant of the yeast culture in flask. ZH646 was then purified using two steps via DEAE-Sephacel chromatography and Mono Q columns. Activity assay showed that ZH646 could significantly stimulate the formation of CFU-Meg and the proliferation of Dami cells in vitro in a dose-dependent manner. In addition, ZH646 also showed thrombopoietic effect in normal mice, and the ability to enhance recovery of normal platelet counts after myelosuppression mice. These results suggested that ZH646 is a novel protein, and its activities are much stronger than that of TPO or IL-6 alone. ZH646 therefore has a broad spectrum of megakaryopoiesis activity associated with platelet production.

Key Words: expression, fusion protein (IL-6/TPO), Pichia pastoris, platelet production, purification

Abbreviations: CFU-Meg, colony forming unit of megakaryocyte; EPO, erythropoietin; FL, Flt-3 ligand; IL-3, interleukin 3; IL-6, Interleukin 6; IL-11, interleukin 11; SCF, stem cell factor; TPO, Thrombopoietin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.